SCHLIEREN, ZURICH /FULL-TIME
Anjarium is a privately held, early-stage biotechnology company focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic disease throughout a patient’s lifetime. The Company’s versatile platform aims to leverage breakthrough science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. We are backed by leading international and strategic investors Abingworth, Gimv, Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
Currently headquartered at Biotechnopark in Zurich, Switzerland, we are rapidly expanding our team and are looking for talented and creative individuals, driven by patient outcomes, to join us. Our team is passionate about building a new generation of durable genetic medicines for life-threatening diseases while pushing forward the frontiers of gene therapy.
About the Role:
The successful candidate will work both independently and as part of a rapidly growing formulations team to develop new lipid nanoparticle formulations to support key studies with Anjarium’s novel payloads. The ideal candidate will have experience with formulation optimization, characterization and downstream assays for a variety of novel nucleic acid payloads. The Nanoparticle Delivery Research Associate will work closely with other individuals from delivery biology, analytics and platform teams at Anjarium.
Qualifications and experience:
Key interpersonal skills: